Amarin (AMRN): Goldman Remains Neutral as Investors Await FDA Response on ANCHOR Appeal

August 8, 2014 1:05 PM

Goldman Sachs maintained a Neutral rating on Amarin Corporation (NASDAQ: AMRN) with a price target of $1.90. Comments follow Q2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found